TNF-CM1R1-100μg / 询价
TNF-CM1R1-500μg / 询价
TNF-CM1R1-500μgx2 / 询价
Cynomolgus TNFR1/CD120a/TNFRSF1A Protein
Recombinant Cynomolgus TNFR1/CD120a/TNFRSF1A Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Leu30-Thr211 [Accession | A0A7N9CVF2].
The protein has a predicted MW of 21.62 kDa. Due to glycosylation, the protein migrates to 32-42 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Cynomolgus TNFR1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Cynomolgus TNFR1 is greater than 95% as determined by SEC-HPLC.
Immobilized Cynomolgus TNFR1, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human TNF alpha, His Tag with the EC50 of 10.7ng/ml determined by ELISA (QC Test).
Cynomolgus TNFR1, His Tag immobilized on CM5 Chip can bind Cynomolgus TNF alpha, His Tag with an affinity constant of 0.23 nM as determined in SPR assay (Biacore T200).
Tumour necrosis factor alpha (TNF-α) is a pleiotropic cytokine with both injurious and protective functions, which are thought to diverge at the level of its two cell surface receptors, TNFR1 and TNFR2. In the setting of acute injury, selective inhibition of TNFR1 is predicted to attenuate the cell death and inflammation associated with TNF-α, while sparing or potentiating the protective effects of TNFR2 signalling.
TNF-R1; TNF-RI; FPF; TBP1; TNF-R55; TNFAR; TNFR60; p55; p60; MS5; p55-R; TNFR1-d2
(1) Proudfoot A, Bayliffe A, O'Kane CM, Wright T, Serone A, Bareille PJ, Brown V, Hamid UI, Chen Y, Wilson R, Cordy J, Morley P, de Wildt R, Elborn S, Hind M, Chilvers ER, Griffiths M, Summers C, McAuley DF. Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury. Thorax. 2018 Aug;73(8):723-730. doi: 10.1136/thoraxjnl-2017-210305. Epub 2018 Jan 29. PMID: 29382797; PMCID: PMC6204954.
